Full Press Release Details
Bio Solutions Adds Quantum TM to 400+ Account
Portfolio Utilizing Breakthrough Fingerprint Drug Testing
Traffic Management transitions from saliva and urine testing to non-invasive, in-house
fingerprint sweat-based drug screening
recent client added to INBS's portfolio of more than 400 accounts across the globe, as the
Company plans entry into the US market
YORK, January 29, 2025 - Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a
medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Quantum Traffic Management
("Quantum TM"), a leading UK-based traffic management provider, has adopted INBS' Intelligent Fingerprinting Drug Testing
Solution across its 10 nationwide sites to increase workplace testing efficiency and safety.
over 30 years of industry experience, Quantum TM operates across the utilities, highways, rail, local authority, and events sectors.
Previously, Quantum TM relied on saliva and urine testing through external occupational health providers; however, the delays and inefficiencies
associated with these methods prompted the company to explore a quicker and more hygienic alternative. INBS' fingerprint sweat-based
system enables Quantum TM to conduct on-the-spot drug screening in-house, facilitating rapid decision-making and improved operational
Intelligent Fingerprinting Drug Testing Solution provides us with greater control when it comes to drug testing. Having previously faced
delays with our former saliva and urine drug testing methods, we needed to find an effective solution that we could manage in-house and
increase our testing productivity," said Scott Powell, Managing Director at Quantum TM. "Intelligent Bio Solutions'
technology enables us to do this, and we have already improved our testing efficiency with rapid, non-invasive screening."
Intelligent Fingerprinting Drug Screening System enables organizations to conduct efficient and accurate drug screening tests without
requiring specialized staff or facilities. Its ability to provide rapid on-site results eliminates many of the challenges associated
with traditional testing methods.
over 400 accounts across 19 countries, INBS continues to lead the evolution of drug screening technology, serving industries including
construction, manufacturing, transport, and logistics. With the Company's recent FDA 510(k) submission in December 2024 and with
plans to enter the US market in 2025, INBS is poised to leverage the rapidly expanding global POC drug screening market.
Quantum Traffic Management
Traffic Management specializes in full-service bespoke traffic management solutions throughout the United Kingdom, catering to the utilities,
highways, rail, local authorities, and event sectors. With over 30 years of experience in a wide range of services, including 12AB (high-speed)
and 12D (rural and urban roads), the company consistently delivers high-quality, tailored solutions with a strong focus on health and
Intelligent Bio Solutions Inc.
Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company
believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis,
which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens
for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection
in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The
Company's current customer segments outside the US include construction, manufacturing and engineering, transport and logistics
firms, drug treatment organizations, and coroners.
more information, visit: http://www.ibs.inc/
of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties.
Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully
develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure
regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or
implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology,
including "believes," "estimates," "anticipates," "expects," "plans," "projects,"
"intends," "potential," "may," "could," "might," "will," "should,"
"approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent
Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this
release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained
in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Pinto, Managing Director
Strategic Communications